Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/15/2026
-
TipRanks Financial Blog
5/15/2026
-
Tickeron - Stocks
5/13/2026
-
TipRanks Financial Blog
5/13/2026
-
Tickeron - Stocks
5/12/2026
-
Business Wire
5/12/2026
-
Business Wire
5/9/2026
-
The Cerbat Gem
5/8/2026
-
MarketBeat
5/6/2026
-
Business Wire
5/6/2026
-
Tickeron - Stocks
5/6/2026
-
Tickeron - Stocks
Neurogene (NGNE, $26.85) entered Downtrend as Momentum indicator drops below 0 level on May 01, 2026
5/2/2026
-
Tickeron - Stocks
5/1/2026
-
Zolmax
4/29/2026
-
MarketBeat
4/28/2026
-
Business Wire
4/28/2026
-
TipRanks Financial Blog
4/28/2026
-
MarketBeat
4/22/2026
-
Tickeron - Stocks
4/20/2026
-
Business Wire
4/20/2026
-
Simply Wall St
4/20/2026
-
FiercePharma
4/18/2026
-
Tickeron - Stocks
4/16/2026
-
Tickeron - Technical Analysis
4/16/2026
-
Tickeron - Technical Analysis
4/15/2026
-
Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, May 12, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
855 508 3568
Address
535 W 24th Street
New York, NY 10011
New York, NY 10011
Country
Year Founded
Business Description
Sector
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an...
more